Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...
Two new medicines for people with chronic lymphocytic leukaemia could be on the way, with Pharmac proposing to fund venetoclax with ibrutinib or with obinutuzumab. If accepted, the combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results